Evan L Brittain

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/403596/publications.pdf

Version: 2024-02-01

86 papers	2,538 citations	201385 27 h-index	223531 46 g-index
89 all docs	89 docs citations	89 times ranked	3271 citing authors

#	Article	IF	Citations
1	Toxin-Mediated Myocarditis From a BrownÂRecluse Spider Bite. JACC: Case Reports, 2022, 4, 49-53.	0.3	1
2	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension. Pulmonary Circulation, 2022, 12, e12028.	0.8	8
3	Cirrhotic cardiomyopathy: Appraisal of the original and revised criteria in predicting posttransplant cardiac outcomes. Liver Transplantation, 2022, 28, 1321-1331.	1.3	20
4	Introduction to Review Series on Pulmonary Vascular Disease and Right Ventricular Heart Failure. Circulation Research, 2022, 130, 1362-1364.	2.0	1
5	A Fluid Challenge Test for the Diagnosis of Occult Heart Failure. Chest, 2021, 159, 791-797.	0.4	19
6	BMI Is Causally Associated With Pulmonary Artery Pressure But Not Hemodynamic Evidence of Pulmonary Vascular Remodeling. Chest, 2021, 159, 302-310.	0.4	9
7	Shuttling toward Improved Clinic-based Assessment of Exercise Capacity in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2021, 18, 26-27.	1.5	0
8	Unexpectedly Low Natriuretic Peptide Levels in Patients With HeartÂFailure. JACC: Heart Failure, 2021, 9, 192-200.	1.9	32
9	NHLBI-CMREF Workshop Report on Pulmonary Vascular DiseaseÂClassification. Journal of the American College of Cardiology, 2021, 77, 2040-2052.	1.2	13
10	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circulation: Heart Failure, 2021, 14, .	1.6	11
11	Postdeployment Respiratory Syndrome in Soldiers With Chronic Exertional Dyspnea. American Journal of Surgical Pathology, 2021, 45, 1587-1596.	2.1	16
12	Association between HIV and incident pulmonary hypertension in US Veterans: a retrospective cohort study. The Lancet Healthy Longevity, 2021, 2, e417-e425.	2.0	6
13	Using genetics to detangle the relationships between red cell distribution width and cardiovascular diseases: a unique role for body mass index. Open Heart, 2021, 8, e001713.	0.9	3
14	Mobile Health Technologies in Cardiopulmonary Disease. Chest, 2020, 157, 654-664.	0.4	59
15	Pulmonary Artery Acceleration Time in Young Adulthood and Cardiovascular Outcomes Later in Life: The Coronary Artery Risk Development in Young Adults Study. Journal of the American Society of Echocardiography, 2020, 33, 82-89.e1.	1.2	2
16	Biomarker-specific differences between transpulmonary and peripheral arterialâ€“venous blood sampling in patients with pulmonary hypertension. Biomarkers, 2020, 25, 131-136.	0.9	2
17	Floating the invisible swan: noninvasive prediction of haemodynamics. European Respiratory Journal, 2020, 55, 1902385.	3.1	0
18	Mechanistic Phase II Clinical Trial of Metformin in Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2020, 9, e018349.	1.6	44

#	Article	IF	Citations
19	HIV- and HCV-specific markers and echocardiographic pulmonary artery systolic pressure among United States veterans. Scientific Reports, 2020, 10, 18729.	1.6	2
20	The polygenic architecture of left ventricular mass mirrors the clinical epidemiology. Scientific Reports, 2020, 10, 7561.	1.6	13
21	Echocardiographic Pulmonary Hypertension and Right Heart Functionâ€"The Big Pictureâ€"Reply. JAMA Cardiology, 2020, 5, 613.	3.0	0
22	Sex hormone exposure and reproductive factors in pulmonary arterial hypertension: a caseâ€"control study. Pulmonary Circulation, 2020, 10, 1-9.	0.8	3
23	FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. Progress in Cardiovascular Diseases, 2020, 63, 184-191.	1.6	25
24	Pulmonary Hypertension and Right Ventricular Failure. Cardiology Clinics, 2020, 38, 269-281.	0.9	4
25	Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. European Respiratory Journal, 2020, 55, 1901486.	3.1	26
26	Six-minute walk distance in healthy young adults. Respiratory Medicine, 2020, 165, 105933.	1.3	43
27	Moment on the Lips, a Lifetime on the Lungs?. Circulation Research, 2019, 125, 467-469.	2.0	0
28	Association of Mild Echocardiographic Pulmonary Hypertension With Mortality and Right Ventricular Function. JAMA Cardiology, 2019, 4, 1112.	3.0	73
29	Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition. JACC: CardioOncology, 2019, 1, 14-23.	1.7	15
30	Correspondence on the debate regarding the haemodynamic definition of pulmonary hypertension. European Respiratory Journal, 2019, 53, 1900727.	3.1	2
31	Early intervention: should we conduct therapeutic trials for mild pulmonary hypertension before onset of symptoms?. Pulmonary Circulation, 2019, 9, 204589401984561.	0.8	6
32	Echocardiographic evaluation of diastolic function in the setting of pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-11.	0.8	9
33	Natriuretic peptide receptor C contributes to disproportionate right ventricular hypertrophy in a rodent model of obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension. Pulmonary Circulation, 2019, 9, 204589401987859.	0.8	20
34	A checkpoint on innate myeloid cells in pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-5.	0.8	9
35	Reduced freeâ€living activity levels in pulmonary arterial hypertension patients. Pulmonary Circulation, 2019, 9, 1-3.	0.8	10
36	Unbiased Phenome-Wide Association Studies of Red Cell Distribution Width Identifies Key Associations with Pulmonary Hypertension. Annals of the American Thoracic Society, 2019, 16, 589-598.	1.5	16

#	Article	IF	Citations
37	Adverse physiologic effects of Western diet on right ventricular structure and function: role of lipid accumulation and metabolic therapy. Pulmonary Circulation, 2019, 9, 1-9.	0.8	20
38	Editorial commentary: Pulmonary hypertension in left heart disease: Definitions, data sources, and the road ahead. Trends in Cardiovascular Medicine, 2019, 29, 218-219.	2.3	0
39	Human PAH is characterized by a pattern of lipid-related insulin resistance. JCI Insight, 2019, 4, .	2.3	69
40	SAT-080 Dexamethasone Administration Stimulates Acute Increases in Natriuretic Peptides in Humans: A Potential Diagnostic Test for "Natriuretic Peptide Hormone Deficiency"?. Journal of the Endocrine Society, 2019, 3, .	0.1	0
41	Autonomic Nervous System in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 925-927.	1.6	7
42	Clinical Features Associated With Nascent Left Ventricular Diastolic Dysfunction in a Population Aged 40 to 55 Years. American Journal of Cardiology, 2018, 121, 1552-1557.	0.7	8
43	Diabetes Mellitus Associates with Increased Right Ventricular Afterload and Remodeling in Pulmonary Arterial Hypertension. American Journal of Medicine, 2018, 131, 702.e7-702.e13.	0.6	20
44	A Metabolic Basis for Endothelial-to-Mesenchymal Transition. Molecular Cell, 2018, 69, 689-698.e7.	4.5	164
45	Redefining pulmonary hypertension. Lancet Respiratory Medicine,the, 2018, 6, 168-170.	5.2	41
46	The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined preâ€•and postâ€•capillary pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-8.	0.8	27
47	Increased Echocardiographic Pulmonary Pressure in HIV-infected and -uninfected Individuals in the Veterans Aging Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 923-932.	2.5	31
48	Bone Marrowâ€“Derived Proangiogenic Cells Mediate Pulmonary Arteriole Stiffening via Serotonin 2B Receptor Dependent Mechanism. Circulation Research, 2018, 123, e51-e64.	2.0	17
49	Features Associated With Discordance Between Pulmonary Arterial Wedge Pressure and Left Ventricular End Diastolic Pressure in Clinical Practice. Chest, 2018, 154, 1099-1107.	0.4	29
50	Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-9.	0.8	5
51	Lack of a Tricuspid Regurgitation Doppler Signal and Pulmonary Hypertension by Invasive Measurement. Journal of the American Heart Association, 2018, 7, .	1.6	53
52	Racial differences in patients referred for right heart catheterization and risk of pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-9.	0.8	17
53	A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1702638.	3.1	183
54	Echocardiographic Pulmonary Artery Systolic Pressure in the Coronary Artery Risk Development in Young Adults (CARDIA) Study: Associations With Race and Metabolic Dysregulation. Journal of the American Heart Association, 2017, 6, .	1.6	20

#	Article	IF	Citations
55	End-Tidal Carbon Dioxide as a Prognostic Feature in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2017, 14, 896-902.	1.5	6
56	Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension. JAMA Cardiology, 2017, 2, 1361.	3.0	122
57	Thermodilution vs Estimated Fick Cardiac Output Measurement in Clinical Practice. JAMA Cardiology, 2017, 2, 1090.	3.0	91
58	Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects. European Respiratory Journal, 2017, 50, 1602337.	3.1	55
59	Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 186-199.	0.8	57
60	Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension. Journal of the American College of Cardiology, 2016, 68, 2525-2536.	1.2	160
61	Measurement of diffuse ventricular fibrosis with myocardial T1 in patients with atrial fibrillation. Journal of Arrhythmia, 2016, 32, 51-56.	0.5	4
62	Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 719-728.	2.5	75
63	Hemodynamic Evidence of Vascular Remodeling in Combined Postâ€•and Precapillary Pulmonary Hypertension. Pulmonary Circulation, 2016, 6, 313-321.	0.8	38
64	Integration of Complex Data Sources to Provide Biologic Insight into Pulmonary Vascular Disease (2015 Grover Conference Series). Pulmonary Circulation, 2016, 6, 251-260.	0.8	11
65	Severity of Pulmonary Hypertension and Obesity are Not Associated with Worse Functional Outcomes after Pulmonary Thromboendarterectomy. Pulmonary Circulation, 2016, 6, 174-180.	0.8	3
66	Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 242-248.	1.4	12
67	Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1936-1944.	1.6	169
68	Vasodilator-Responsive Idiopathic Pulmonary Arterial Hypertension: Evidence for a New Disease?. Annals of Internal Medicine, 2015, 162, 148-149.	2.0	6
69	Feasibility and Diagnostic Potential of Pulmonary Transit Time Measurement by Contrast Echocardiography: A Pilot Study. Echocardiography, 2015, 32, 1564-1571.	0.3	16
70	Effect of Acute Arteriolar Vasodilation on Capacitance and Resistance in Pulmonary Arterial Hypertension. Chest, 2015, 147, 1080-1085.	0.4	20
71	Right Ventricular Protein Expression Profile in Endâ€Stage Heart Failure. Pulmonary Circulation, 2015, 5, 481-497.	0.8	19
72	National Institutes of Health Career Development Awards for CardiovascularÂPhysicianâ€“Scientists. Journal of the American College of Cardiology, 2015, 66, 1816-1827.	1.2	12

#	Article	IF	Citations
73	Letter by Mosley Regarding Article, â€œIron Homeostasis and Pulmonary Hypertension: Iron Deficiency Leads to Pulmonary Vascular Remodeling in the Ratâ€• Circulation Research, 2015, 117, e56-7.	2.0	2
74	Evidence for Right Ventricular Lipotoxicity in Heritable Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 325-334.	2.5	146
75	Impact of Diabetes on Survival and Right Ventricular Compensation in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2014, 4, 311-318.	0.8	50
76	One generationâ€™s â€œjunkâ€•is anotherâ€™s treasure: The emerging role of microRNAs as therapeutic targets. Journal of Heart and Lung Transplantation, 2014, 33, 233-234.	0.3	1
77	Minimally invasive fibrillating mitral valve replacement for patients with advanced cardiomyopathy: A safe and effective approach to treat a complex problem. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 2045-2051.e1.	0.4	6
78	Challenges Facing Early Career Academic Cardiologists. Journal of the American College of Cardiology, 2014, 63, 2199-2208.	1.2	51
79	Elevation of Plasma Cell-Free Hemoglobin in Pulmonary Arterial Hypertension. Chest, 2014, 146, 1478-1485.	0.4	34
80	Right Ventricular Pathobiology. , 2014, , 35-44.		0
81	Prostanoids But Not Oral Therapies ImproveÂRight Ventricular Function in Pulmonary Arterial Hypertension. JACC: Heart Failure, 2013, 1, 300-307.	1.9	31
82	Shorter Survival in Familial versus Idiopathic Pulmonary Arterial Hypertension is Associated with Hemodynamic Markers of Impaired Right Ventricular Function. Pulmonary Circulation, 2013, 3, 589-598.	0.8	30
83	Echocardiographic Assessment of the Right Heart in Mice. Journal of Visualized Experiments, 2013, , .	0.2	18
84	Predictors of Diastolic-To-Wedge Gradient in Patients Evaluated for Pulmonary Hypertension. PLoS ONE, 2013, 8, e76461.	1.1	1
85	Right Ventricular Plasticity and Functional Imaging. Pulmonary Circulation, 2012, 2, 309-326.	0.8	27
86	Acute Improvement in Right Ventricular Function after Treatment of Presumed Massive Pulmonary Embolism with Thrombolytics. Pulmonary Circulation, 2012, 2, 522-524.	0.8	20